BioMarin plots comeback year, with plans to turn around profits and head back to the FDA with rejected gene therapy

Nicole DeFeudis

Editor

Could this be a comeback year for BioMarin? CEO Jean-Jacques Bienaimé certainly hopes so, as he plans to finally turn the corner on profitability and …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BioMarin plots comeback year, with plans to turn around profits and head back to the FDA with rejected gene therapy

Nicole DeFeudis

Editor

Sign up to read this article for free.

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Alcon tried to sink Aurion's IPO in 'Valentine's Day massacre,' new lawsuits say

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

How AI can address ongoing challenges in the life sciences industry

Bio­Marin plots come­back year, with plans to turn around prof­its and head back to the FDA with re­ject­ed gene ther­a­py

Nicole DeFeudis

Editor

Sign up to read this article for free.

Some FDA med­ical de­vice staff re­in­stat­ed just days af­ter re­ceiv­ing pink slips

Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos

Post-Hoc: Phar­ma CEOs' al­ter­na­tive re­al­i­ty with Trump

Al­con tried to sink Au­ri­on's IPO in 'Valen­tine's Day mas­sacre,' new law­suits say

Pfiz­er hires ex-FDA deputy Pa­trizia Cavaz­zoni as chief med­ical of­fi­cer

How AI can ad­dress on­go­ing chal­lenges in the life sci­ences in­dus­try

BioMarin plots comeback year, with plans to turn around profits and head back to the FDA with rejected gene therapy

Some FDA medical device staff reinstated just days after receiving pink slips

Pfizer wants in on Summit’s goal to beat Keytruda via ADC combos

Post-Hoc: Pharma CEOs' alternative reality with Trump

Alcon tried to sink Aurion's IPO in 'Valentine's Day massacre,' new lawsuits say

Pfizer hires ex-FDA deputy Patrizia Cavazzoni as chief medical officer

How AI can address ongoing challenges in the life sciences industry